Zimmer Biomet Holdings Inc (N:ZBH)

Business Focus: Medical Equipment, Supplies & Distribution

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
 
See Regulatory Filings on SEC
Company Contact
Address: 345 E Main St
WARSAW IN 46580-2746
Tel: N/A
Website: https://www.zimmerbiomet.com/en
IR: See website
<
Key People
Ivan Tornos
President, Chief Executive Officer, Director
Suketu P. Upadhyay
Chief Financial Officer, Executive Vice President - Finance, Operations and Supply Chain
Wilfred Van Zuilen
President - Europe, Middle East and Africa
Sang Yi
President, Asia Pacific
Lori Winkler
Chief Human Resource Officer, Senior Vice President
Chad F. Phipps
Senior Vice President, General Counsel, Secretary
Rachel Ellingson
Senior Vice President, Chief Strategy Officer, Executive Officer
Paul A. Stellato
Chief Accounting Officer, Vice President, Controller
 
Business Overview
Zimmer Biomet Holdings, Inc. is a global medical technology company. Its segments include Americas, EMEA, and Asia Pacific. The Company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic (CMFT) products; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its other product category primarily includes its robotic, surgical and bone cement products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee, and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System, and G7 Acetabular System. Its S.E.T. product category includes sports medicine, biologics, foot and others.
Financial Overview
For the fiscal year ended 31 December 2023, Zimmer Biomet Holdings Inc revenues increased 7% to $7.39B. Net income before extraordinary items increased from $290.2M to $1.02B. Revenues reflect Americas segment increase of 8% to $4.62B, EMEA segment increase of 9% to $1.59B, Americas segment increase of 8% to $4.62B, EMEA segment increase of 9% to $1.59B. Net income benefited from Unallocated segment loss decrease of 15% to $1.62B.
Employees: 18,000 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $32,548M as of Dec 31, 2023
Annual revenue (TTM): $7,394M as of Dec 31, 2023
EBITDA (TTM): $2,425M as of Dec 31, 2023
Net annual income (TTM): $1,024M as of Dec 31, 2023
Free cash flow (TTM): $691.50M as of Dec 31, 2023
Net Debt Last Fiscal Year: $5,352M as of Dec 31, 2023
Shares outstanding: 205,084,022 as of Feb 14, 2024
Index Membership: S&P 500
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.